Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Revenue (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Revenue for 2 consecutive years, with $50.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Revenue rose 416766.67% year-over-year to $50.0 million, compared with a TTM value of $99.5 million through Jun 2025, changed N/A, and an annual FY2024 reading of $50.0 million, up 119147.62% over the prior year.
  • Revenue was $50.0 million for Q2 2025 at Kairos Pharma, roughly flat from $50.0 million in the prior quarter.
  • Across five years, Revenue topped out at $50.0 million in Q1 2025 and bottomed at -$537000.0 in Q3 2024.